BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26223921)

  • 1. Effect of Qing'e formula on circulating sclerostin levels in patients with postmenopausal osteoporosis.
    Yang YP; Shuai B; Shen L; Xu XJ; Ma C; Lv L
    J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):525-530. PubMed ID: 26223921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Qing'e formula on the in vitro differentiation of bone marrow-derived mesenchymal stem cells from proximal femurs of postmenopausal osteoporotic mice.
    Shuai B; Shen L; Zhu R; Zhou P
    BMC Complement Altern Med; 2015 Jul; 15():250. PubMed ID: 26205885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-calcium, vitamin D fortified milk is effective in improving bone turnover markers and vitamin D status in healthy postmenopausal Chinese women.
    Kruger MC; Ha PC; Todd JM; Kuhn-Sherlock B; Schollum LM; Ma J; Qin G; Lau E
    Eur J Clin Nutr; 2012 Jul; 66(7):856-61. PubMed ID: 22644348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
    Catalano A; Morabito N; Basile G; Brancatelli S; Cucinotta D; Lasco A
    J Clin Endocrinol Metab; 2013 May; 98(5):1911-5. PubMed ID: 23596142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with Qing'E, a kidney-invigorating Chinese herbal formula, antagonizes the estrogen decline in ovariectomized mice.
    Xu Y; Zhang ZJ; Geng F; Su SB; White KN; Bligh SW; Branford-White CJ; Wang ZT
    Rejuvenation Res; 2010 Aug; 13(4):479-88. PubMed ID: 20707715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women].
    Guan YT; Cai LL; Ding HX; Chen GD; Hu Y
    Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):571-4. PubMed ID: 21029610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis.
    Gatti D; Viapiana O; Idolazzi L; Fracassi E; Ionescu C; Dartizio C; Troplini S; Kunnathully V; Adami S; Rossini M
    Bone; 2014 Oct; 67():189-92. PubMed ID: 25003812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis.
    Karadag-Saygi E; Akyuz G; Bizargity P; Ay P
    Gynecol Endocrinol; 2011 Dec; 27(12):1033-6. PubMed ID: 21627558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physical performance and life quality in postmenopausal women supplemented with vitamin D: a two-year prospective study.
    Gao LH; Zhu WJ; Liu YJ; Gu JM; Zhang ZL; Wang O; Xing XP; Xu L
    Acta Pharmacol Sin; 2015 Sep; 36(9):1065-73. PubMed ID: 26279157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum sclerostin levels associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis.
    Xu XJ; Shen L; Yang YP; Lu FR; Zhu R; Shuai B; Li CG; Wu MX
    Chin Med J (Engl); 2013 Jul; 126(13):2480-4. PubMed ID: 23823821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis.
    Nuti R; Bianchi G; Brandi ML; Caudarella R; D'Erasmo E; Fiore C; Isaia GC; Luisetto G; Muratore M; Oriente P; Ortolani S
    Rheumatol Int; 2006 Mar; 26(5):445-53. PubMed ID: 16283320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Sarioglu M; Tuzun C; Unlu Z; Tikiz C; Taneli F; Uyanik BS
    Rheumatol Int; 2006 Jan; 26(3):195-200. PubMed ID: 15580349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study.
    Rhee Y; Kang M; Min Y; Byun D; Chung Y; Ahn C; Baek K; Mok J; Kim D; Kim D; Kim H; Kim Y; Myoung S; Kim D; Lim SK
    Osteoporos Int; 2006 Dec; 17(12):1801-7. PubMed ID: 17019520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
    Reginster JY; Lecart MP; Richy F
    J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
    Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
    J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
    Ringe JD; Farahmand P; Schacht E; Rozehnal A
    Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in vitamin D metabolites during teriparatide treatment.
    Cosman F; Dawson-Hughes B; Wan X; Krege JH
    Bone; 2012 Jun; 50(6):1368-71. PubMed ID: 22426307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: a randomised controlled trial.
    Hooshmand S; Brisco JR; Arjmandi BH
    Br J Nutr; 2014 Jul; 112(1):55-60. PubMed ID: 24780728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.